Imaging genomics, imaging-omics, and big data
Rivka R. Colen, The University of Texas MD Anderson Cancer Center, Houston, TX

Radiomics and radiogenomics
Robert J. Gillies, Moffitt Cancer Center & Research Institute, Tampa, FL

Title to be announced
Eliot Siegel, University of Maryland, Baltimore, MD

Radiogenomics: Imaging and big data
Michael D. Kuo, University of California Los Angeles, CA

Nanoparticle cancer therapeutics: From concept to clinic
Mark E. Davis, California Institute of Technology, Pasadena, CA

New frontiers: Combining molecular imaging and nanomedicine to light up and selectively destroy cancer
Tayyaba Hasan, Harvard Medical School/Massachusetts General Hospital, Boston, MA

Title to be announced
Naomi Halas, Rice University, Houston, TX

Targeted Radiotherapy: Current status and new directions
Carolyn J. Anderson, University of Pittsburgh Medical Center, Pittsburgh, PA
 

Opportunities and needs for molecular imaging in melanoma
Michael A. Davies, The University of Texas MD Anderson Cancer Center, Houston, TX

The development and imaging of advanced cancer models
Scott K. Lyons, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY

Mouse models to study sensitivity and resistance to targeted therapies in lung cancer
Katerina A. Politi, Yale Cancer Center, New Haven, CT

Approaches to study tumor-stroma interactions through imaging in mouse models of cancer
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Title to be announced
Kimberly A. Kelly, University of Virginia, Charlottesville, VA

New ligands for molecular imaging
Kathlynn C. Brown, SRI International, Harrisonburg, VA

Radiotracers for imaging tumor cell proliferation and quiescence with PET
Robert H. Mach, University of Pennsylvania, Philadelphia, PA

Title to be announced
Eric O. Aboagye, Imperial College London, London, England

Opening Keynote Session

Keynote Address: Targeting PI3K for cancer therapy
Lewis C. Cantley, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, New York, NY

Plenary Session 1:  Immunotherapy and Imaging

Immune biology of allogeneic transplantation
Robert S. Negrin, Stanford Univ. School of Medicine, Stanford, CA

Imaging immune responses in cancer therapy
Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles CA

The synthetic biology of CAR T Cells
Michael C. Jensen, Seattle Children’s Research Institute, Seattle, WA

Plenary Session 2: Theranostics and Companion Diagnostics

Imaging and theranostics in prostate cancer
Martin G. Pomper, Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD

Advancing Personalized Nuclear Medicine by THERANOSTICS of Prostate Cancer Using Ga-68 and Lu-177 Labeled PSMA Small Molecules
Richard P. Baum, Zentralklinik, Germany

Molecular imaging for drug development and selection of targeted treatment in advnaced disease
E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, the Netherlands

Plenary Session 4:  Image-guided Therapy

Tumor Paint molecular imaging agents for intra-operative guidance in solid tumor
surgeries
James M. Olson, Fred Hutchinson Cancer Research Center, Seattle, WA

Molecular imaging guided therapy and applications in radiation oncology
Christina Tsien, University of Michigan, Ann Arbor, MI

Title to be announced
Nancy Lee, Memorial Sloan Kettering Cancer Center, New York, NY

Intravital lineage tracing to study dynamics of tumor growth and metastasis
Anoek Zomer, Hubrecht Institute, Utrecht, The Netherlands

Title to be announced
Christopher H. Contag, Stanford University, Stanford, CA

Molecular iImaging targets for epithelial cancer stem cells
Michael F. Clarke, Stanford University, Stanford, CA

New methods for assessing cellular metabolic heterogeneity
Melissa Skala, Vanderbilt University, Nashville, TN

Utilizing hyperpolarized MR to interrogate real-time tumor metabolism in vivo
Kayvan Keshari, Memorial Sloan Kettering Cancer Center, New York, NY

Metabolic heterogeneity of cancer cells in culture and in vivo
Ralph DeBerardinis, UT Southwestern Medical Ctr., Dallas, TX

Molecular imaging as a cancer biomarker in clinical trials
David A. Mankoff, University of Pennsylvania, Philadelphia, PA

Clinical applications of quantitative imaging in planning and assessing cancer therapies
Richard L. Wahl, Johns Hopkins Univ. School of Medicine, Baltimore, MD


Design of clinical trials and approaches to prediction and assessment of response
Anthony F. Shields, Barbara Ann Karmanos Cancer Inst., Wayne State, Detroit, MI

Panelists
Robert E. Reiter, UCLA, Los Angeles, CA
Gabe Canales, Blue Cure Foundation, Houston, TX
Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY
Martin G. Pomper, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
 

Plenary Session 8: Tumor Microenvironment and Inflammation

Inflammation and cancer: Immune cells as targets for anti-cancer therapyLisa M. Coussens, OHSU Knight Cancer Inst., Portland, OR

Targeting the stroma in pancreas cancer: The unexpected outcome
Valerie Lebleu, The University of Texas MD Anderson Cancer Center

Intravital imaging reveals how BRaf inhibition generates drug-tolerant microenvironments
Erik Sahai, Cancer Research UK, London, England

Extracellular vesicles/RNA as tactics in glioblastoma progression
Xandra O. Breakefield, Massachusetts General Hospital, Boston, MA

Metastasis-promoting functions of tumor-derived exosomes
Yibin Kang, Princeton University, Princeton, NJ

Title to be announced
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX